Long-term prospective follow-up study of cardiac function after cardiotoxic therapy for malignancy in children.
OBJECTIVE
To evaluate cardiac function by means of conventional and three-dimensional echocardiography (3DE) and measurement of natriuretic peptides in children and adolescents previously treated for childhood malignancy using individual follow-up data and matched control children as reference criteria.


METHODS
Thirty-nine survivors of childhood malignancy were examined in 1994 and 1998. The mean time from the diagnosis was 8.6 (3.9 to 16.8) years and between cardiac evaluations was 4.1 (3.3 to 5.1) years. Patients were divided into two groups according to therapies given (group I (n = 30): no cardiac irradiation, median cumulative anthracycline dose 210 mg/m2; group II (n = 9): irradiation in the cardiac region, median cumulative anthracycline dose 180 mg/m2).


RESULTS
Fractional shortening (FS) in 1994 was higher than in 1998 (32.5 +/- 4.3 vs. 30.3% +/- 3.3%, P =.009). 33% of patients in group I and 56% in group II in 1994 and 30% of patients in group I and 67% in group II in 1998 had N-terminal of the propeptide-atrial natriuretic peptide (NT-proANP) levels exceeding the 90th percentile of controls. In 1998, both groups (I and II) had lower ejection fraction (EF) measured by 3DE than their matched controls (52.9 +/- 5.2 vs. 58.8% +/- 3.1%, P <.001 and 50.0 +/- 6.6 vs. 60.8% +/- 3.2%, P =.024, respectively). Left atrial maximum volumes/body surface area were smaller in the patients than in controls. B-Type natriuretic peptide values did not differ significantly in either group.


CONCLUSIONS
Left ventricular contractility decreases slowly even years after cardiotoxic cancer therapy in children. 3DE and NT-proANP measurements are effective methods to evaluate the cardiac function in these patients.
Poutanen
Tuija
T
Department of Pediatrics, Kuopio University Hospital, Finland. tuija.poutanen@koti.tpo.fi
Tikanoja
Tero
T
Riikonen
Pekka
P
Silvast
Annuli
A
Perkkiö
Mikko
M
D000293:Adolescent; D018943:Anthracyclines / Q000009:adverse effects*; D019540:Area Under Curve; D009320:Atrial Natriuretic Factor / Q000097:blood*; D002319:Cardiovascular System / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000503:physiopathology*; D002648:Child; D004452:Echocardiography; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016015:Logistic Models; D008297:Male; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric
D018943:Anthracyclines; D009320:Atrial Natriuretic Factor